Repositioning generic drugs: Empirical Findings & Policy Implications

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Repositioning generic drugs: Empirical Findings & Policy Implications. / Liddicoat, Johnathon; Liddell, Kathleen ; Darrow, Jonathan; Aboy, Mateo; Jordan, Matthew; Crespo, Cristina; Minssen, Timo.

I: IIC International Review of Intellectual Property and Competition Law, Bind 53, Nr. 9, 2022, s. 1287-1322.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Liddicoat, J, Liddell, K, Darrow, J, Aboy, M, Jordan, M, Crespo, C & Minssen, T 2022, 'Repositioning generic drugs: Empirical Findings & Policy Implications', IIC International Review of Intellectual Property and Competition Law, bind 53, nr. 9, s. 1287-1322. https://doi.org/10.1007/s40319-022-01241-3

APA

Liddicoat, J., Liddell, K., Darrow, J., Aboy, M., Jordan, M., Crespo, C., & Minssen, T. (2022). Repositioning generic drugs: Empirical Findings & Policy Implications. IIC International Review of Intellectual Property and Competition Law, 53(9), 1287-1322. https://doi.org/10.1007/s40319-022-01241-3

Vancouver

Liddicoat J, Liddell K, Darrow J, Aboy M, Jordan M, Crespo C o.a. Repositioning generic drugs: Empirical Findings & Policy Implications. IIC International Review of Intellectual Property and Competition Law. 2022;53(9):1287-1322. https://doi.org/10.1007/s40319-022-01241-3

Author

Liddicoat, Johnathon ; Liddell, Kathleen ; Darrow, Jonathan ; Aboy, Mateo ; Jordan, Matthew ; Crespo, Cristina ; Minssen, Timo. / Repositioning generic drugs: Empirical Findings & Policy Implications. I: IIC International Review of Intellectual Property and Competition Law. 2022 ; Bind 53, Nr. 9. s. 1287-1322.

Bibtex

@article{fc77527bf11b45b585a6e72391c609a4,
title = "Repositioning generic drugs: Empirical Findings & Policy Implications",
abstract = "Commentators claim that drug repositioning (ie developing new uses for authorised drugs) significantly slows when generics are authorised and, therefore, law reform is necessary to encourage more R&D. This study empirically examines this claim by analysing records of clinical trials. It finds that once generics are authorised: i) commercial trials continue at {\textquoteleft}active{\textquoteright} rates for approximately half of the drugs studied, and ii) the number of hospital and university trials actually increases. These findings cast doubt on whether additional incentives are needed. They also indicate that a more effective way to reposition drugs is for recently established government programmes to embrace IP strategies and leverage the hospital and university trials as an R&D pipeline.Keywords: drug repositioning, patent law, regulatory protection, clinical trials, empirical study, generic drugs.",
author = "Johnathon Liddicoat and Kathleen Liddell and Jonathan Darrow and Mateo Aboy and Matthew Jordan and Cristina Crespo and Timo Minssen",
year = "2022",
doi = "10.1007/s40319-022-01241-3",
language = "English",
volume = "53",
pages = "1287--1322",
journal = "IIC International Review of Intellectual Property and Competition Law",
issn = "0018-9855",
publisher = "Verlag C.H./Beck oHG",
number = "9",

}

RIS

TY - JOUR

T1 - Repositioning generic drugs: Empirical Findings & Policy Implications

AU - Liddicoat, Johnathon

AU - Liddell, Kathleen

AU - Darrow, Jonathan

AU - Aboy, Mateo

AU - Jordan, Matthew

AU - Crespo, Cristina

AU - Minssen, Timo

PY - 2022

Y1 - 2022

N2 - Commentators claim that drug repositioning (ie developing new uses for authorised drugs) significantly slows when generics are authorised and, therefore, law reform is necessary to encourage more R&D. This study empirically examines this claim by analysing records of clinical trials. It finds that once generics are authorised: i) commercial trials continue at ‘active’ rates for approximately half of the drugs studied, and ii) the number of hospital and university trials actually increases. These findings cast doubt on whether additional incentives are needed. They also indicate that a more effective way to reposition drugs is for recently established government programmes to embrace IP strategies and leverage the hospital and university trials as an R&D pipeline.Keywords: drug repositioning, patent law, regulatory protection, clinical trials, empirical study, generic drugs.

AB - Commentators claim that drug repositioning (ie developing new uses for authorised drugs) significantly slows when generics are authorised and, therefore, law reform is necessary to encourage more R&D. This study empirically examines this claim by analysing records of clinical trials. It finds that once generics are authorised: i) commercial trials continue at ‘active’ rates for approximately half of the drugs studied, and ii) the number of hospital and university trials actually increases. These findings cast doubt on whether additional incentives are needed. They also indicate that a more effective way to reposition drugs is for recently established government programmes to embrace IP strategies and leverage the hospital and university trials as an R&D pipeline.Keywords: drug repositioning, patent law, regulatory protection, clinical trials, empirical study, generic drugs.

U2 - 10.1007/s40319-022-01241-3

DO - 10.1007/s40319-022-01241-3

M3 - Journal article

VL - 53

SP - 1287

EP - 1322

JO - IIC International Review of Intellectual Property and Competition Law

JF - IIC International Review of Intellectual Property and Competition Law

SN - 0018-9855

IS - 9

ER -

ID: 306454713